Leukemia, Myeloid, Acute research hub
13 indexed studies · 7 currently recruiting
- enrolling by invitationPHASE1
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
This study helps us understand the long-term safety of new treatments for certain cancers like leukemia and lymphoma. People who have already been in an earlier drug trial for these conditions will continue to be monitored to see how they respond over time.
Australia · Belgium · Denmark - recruitingPHASE1, PHASE2
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
This study looks at a new treatment called MK-1045 for two types of non-Hodgkin lymphoma: follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). Researchers want to see if MK-1045 is safe and helps shrink the cancer.
United States · Argentina · Australia - active not recruitingPHASE1
A Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R B-Cell NHL)
This study is testing new combinations of drugs for a type of blood cancer called Non-Hodgkin Lymphoma. It's for people whose lymphoma has come back or hasn't responded to previous treatments. The main goal is to find a safe and effective dose of these new medications.
Australia · Spain · Taiwan - recruitingNA
Evaluation of the Role of Connected Scales in the Therapeutic Care of Hematology Patients
This study looks at how special 'smart' weighing scales can help doctors keep an eye on patients with certain blood cancers like lymphoma and myeloma. Patients will use the scales daily at home, and the medical team will check the readings remotely to spot any changes early.
France - recruitingPHASE4
Clinical Trial Assessing the Immunogenicity of an Anti-pneumococcal Vaccination Strategy (PCV13+PPV23 Versus PREVENAR20) in Adult Patients Treated for a Lymphoma
This study compares different pneumonia vaccines in adults with lymphoma. We're looking at how well the immune system responds to two common vaccines given separately versus one newer vaccine, to see which offers better protection against pneumonia.
France - recruitingPHASE1
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
This study is testing a new medicine, TLN-121, for people with certain types of non-Hodgkin lymphoma that has come back or hasn't responded to other treatments. Doctors want to see if it's safe, how it works in the body, and if it can help shrink the cancer.
United States · Australia · Canada - active not recruitingPHASE4
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
This study helps people with certain cancers or GvHD who are already taking ibrutinib and benefiting from it. It allows them to keep getting the medication if they can't get it commercially and helps researchers learn more about its long-term use.
United States · Australia · Canada - recruitingPHASE1
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
This study is testing a new drug, LY4152199, for people with certain types of B-cell lymphoma that have returned or not responded to previous treatments. Researchers want to find the best dose and see how safe and effective it is.
United States · Australia · Canada - active not recruitingPHASE1, PHASE2
A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)
This study is looking into a new treatment, CC-99282, for non-Hodgkin lymphoma that has returned or not responded to other treatments. Researchers want to see how safe it is and how well it works, both by itself and with other lymphoma medicines.
United States · Argentina · Austria - active not recruitingPHASE1, PHASE2
A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
This study looks at new drug combinations for people with certain types of Non-Hodgkin's Lymphoma that have come back or not responded to previous treatments. It aims to check safety and how well the new treatments work.
United States · Australia · Belgium - active not recruitingPHASE1, PHASE2
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
This study is testing a new cell therapy called Prizlo-Cel for adults with certain types of B-cell non-Hodgkin lymphoma that has returned or is hard to treat. It aims to see if this treatment, which uses your own specially modified cells, is safe and effective.
United States · Australia · Canada - active not recruitingPHASE2
A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)
This study is testing a new cell therapy called JCAR017 for adults with certain types of non-Hodgkin lymphoma that has returned or hasn't responded to other treatments. It aims to see how well it works and if it's safe.
United States · Austria · Canada - recruitingPHASE1, PHASE2
A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies
This study is testing a new medicine, ALETA-001, for people with certain types of B-cell lymphoma. It's for those who have already had a specific CAR T-cell treatment. The study will look at how safe and effective ALETA-001 is.
United Kingdom